HBI-3000: A Novel anti-arrhythmic compound
- Multi-ion channel blocker with efficacy in "gold standard" animal models and low pro-arrhythmic activity
- Safe and low risk (minimum effect on hERG channel)
- Oral and iv formulation in development
- Well tolerated in Chinese Phase 1 with attractive PK profile
- Potential for use in both atrial and ventricular arrhythmias
- Pharmacology and toxicology studies ongoing in US
- Successful Pre-IND meeting with US FDA: Plan acceptable, including use of Chinese clinical data
- Phase 2 in China pending
About Anti-Arrhythmic drugs
Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases they carry significant safety risk. The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease, precluding treatment with most existing anti-arrhythmic drugs for a majority of patients. Development of safe anti-arrhythmic agents is needed. Data suggest that HBI-3000 may have safety advantages over other anti-AF agents and may also have potential for use in treating ventricular arrhythmias. Worldwide licensing rights ex-China are available for HBI-3000.